Latest Dilution News

Cadoux Limited has made significant progress in its High Purity Alumina (HPA) project and its 50% owned Minhub rare earths processing initiative, advancing engineering design and market engagement amid growing global demand for critical minerals.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

ioneer Ltd has raised approximately US$50.4 million through an institutional placement to fund the advancement of its Rhyolite Ridge lithium-boron project in Nevada towards a Final Investment Decision in the second half of 2026. The capital injection supports project readiness, environmental permitting, and early works for this strategically significant US critical minerals asset.

WAM Active Limited has launched a $70.7 million entitlement offer at a 7.8% discount, complemented by a $19.3 million placement, following a stellar 40.6% year-to-date portfolio performance. The capital raise aims to fuel further investment in Australian equities.

Arcadia Minerals Limited has voluntarily suspended trading of its shares pending a significant announcement about a capital raising and earn-in deal at the Swanson Tantalum mine.

archTIS Limited reports a remarkable 308% increase in annual recurring revenue, driven by deepening ties with the U.S. Department of Defense and strategic Spirion acquisition integration.

Horizon Minerals Ltd reported a solid quarterly cash flow increase of A$3.1 million, ending December 2025 with A$37.5 million in cash and equivalents. The company also extinguished its Nebari Convertible Loan Facility, signaling a cleaner capital structure ahead.

WAM Active Limited has announced a significant capital raising through a pro-rata entitlement offer and a placement, aiming to bolster its investment capacity without materially affecting company control.

Nagambie Resources and Alkane Resources have entered a binding agreement for a joint venture that could see Alkane invest up to $27.5 million to earn an 80% stake in Nagambie's key mining tenements, leveraging Alkane’s existing processing infrastructure to accelerate production.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.